Cancer Research Technology
Log in Register
Menu
Search
Cell Lines

A2780 PTX(128) resistant cell line

Invented by Dr Jolanta Szenajch from Military Institute of Medicine, Warsaw, Poland , Dr Luiza Handschuh from Institute of Bioorganic Chemistry Polish Academy of Sciences , Dr Aleksandra Świercz from Institute of Bioorganic Chemistry Polish Academy of Sciences , Dr Michal Góralski from Institute of Bioorganic Chemistry Polish Academy of Sciences , Dr Alicja Szabelska-Beręsewicz from Poznań University of Life Science , Prof Idzi Siatkowski from Poznań University of Life Science , Dr Joanna Zyprych-Walczak from Poznań University of Life Science
Invented at Military Institute of Medicine, Warsaw, Poland
  • Datasheet
  • Inventor Info
Print

Info

Image thumbnail for A2780 PTX(128) resistant cell line
Image thumbnail for A2780 PTX(128) resistant cell line
Image thumbnail for A2780 PTX(128) resistant cell line
Image thumbnail for A2780 PTX(128) resistant cell line
Image thumbnail for A2780 PTX(128) resistant cell line
Add an image
Figure 1. The family tree of A2780 cell sublines with acquired resistance to PTX. A2780 parental cell line and six sublines, chosen for further studies, are bolded. The schedule of PTX treatment for each cell line is described as e.g. (4+7+27)d* - 4 days of 2 nM PTX treatment, 7 days of recovery and 27 days of 2 nM PTX retreatment; totally 31 days of drug treatment were needed for cell adaptation to 2 nM PTX concentration. Reprinted from Szenajch J. et al. 2020. Int. J. Mol. Sci. 21(23): 9218.
Figure 2. Dose-response curves to PTX and CDDP for parental A2780 cell line and six sublines with PTX-induced inverse resistance to PTX and CDDP (a) Resistance to PTX systematically elevates with increasing tolerated doses of PTX. (b) Resistance to CDDP declines with increasing tolerated doses of PTX. Reprinted from Szenajch J. et al. 2020. Int. J. Mol. Sci. 21(23): 9218.
Figure 3. A2780 PTX (128) Cell Line. 24 hours after plating. Reprinted from Szenajch J. et al. 2020. Int. J. Mol. Sci. 21(23): 9218.
Figure 4. A2780 PTX (128) Cell Line 120 hours after plating. Ready for subculture. Reprinted from Szenajch J. et al. 2020. Int. J. Mol. Sci. 21(23): 9218.
Table 1. The values of IC50(120hr) for PTX and CDDP in parental A2780 cell line and six sublines with PTX-developed inverse resistance to PTX and CDDP. Reprinted from Szenajch J. et al. 2020. Int. J. Mol. Sci. 21(23): 9218.
Add an image
Image thumbnail for A2780 PTX(128) resistant cell line Image thumbnail for A2780 PTX(128) resistant cell line Image thumbnail for A2780 PTX(128) resistant cell line Image thumbnail for A2780 PTX(128) resistant cell line Image thumbnail for A2780 PTX(128) resistant cell line
Catalogue Number 160734
Antigen/Gene or Protein Targets Paclitaxel resistance
Parental Line A2780
Host Human
Tissue Ovary
Disease Keywords Ovarian Cancer 
Model Tumour line
Relevance The paclitaxel (PTX) resistant A2780 PTX (128) cell line with collateral sensitivity to cisplatin (inverse resistance) has been developed by continuous growing of A2780 PTX (64) parental cell line (cat. no160733) in 128 nM PTX concentration (for details see Fig. 1). The half maximal inhibitory concentration (IC50) for PTX is about fifty nine times as high the IC50 for A2780, whereas for CDDP it is about five times lower (for details see Tab. 1). PTX and CDDP are standard chemotherapeutic drugs used in the treatment of ovarian cancer and acquired resistance to them remains a major obstacle in therapy. The trend of developing the inverse resistance is dominant in clinical practice, so A2780 PTX (128) cell line with other sublines of the series (see Notes for details) can be used as a primary tool for deciphering the molecular and cellular mechanisms of drug resistance in ovarian cancer.
Production Details Split sub-confluent cultures (70-80%) seeding at 4 x 1000 (tolerated range: 1 x 1000 to 1 x 10 0000) cells/cm2 using TrypLE ExpressTM, 5% CO2, 37oC. Culture cells without drug until they have been fully adhered (after 24 h).
Research Area Cancer, Drug Discovery & Development
Growth/Phenotype Keywords Adherent
Recommended Growing Conditions RPMI 1640 medium + 2mM L-alanine-L-glutamine (GlutaMAXTM) + 5% heat-inactivated Foetal Bovine Serum (FBS) , at 37oC and 5% CO2. To keep the stability of resistance profile not using antibiotics and antimycotics is recommended. Cells should be cultured without PTX (up to 10 days) to avoid the resistance escalation. After this time the maintenance treatment with 128 nM PTX for one passage is recommended.
Notes This cell line was generated as part of a series of isogenic ovarian cancer lines with gradually changing inverse resistance to PTX (resistant) and CDDP (sensitive); see A2780 PTX (4) Cat no:160729, A2780 PTX (8) Cat no:160730, A2780 PTX (16) Cat no:160731, A2780 PTX (32) Cat no:160732, and A2780 PTX (64) Cat no:160733 for the others (see Tab. 1 and Fig. 2 for details). Transcriptomes of six sublines were sequenced and the mRNA dataset was deposited under Gene Expression Omnibus Accession No GSE159791.

Patent number: 233178

References

There are 1 reference entries for this reagent.

View All References

References: 1 entry

Szenajch et al. 2020. Int. J. Mol. Sci. 21(23): 9218. PMID: 33287223

View  

Add a reference

References: 1 entry

Szenajch et al. 2020. Int. J. Mol. Sci. 21(23): 9218. PMID: 33287223

View  

Add a reference

Inventor Information

Inventors

Dr Jolanta Szenajch
Dr Jolanta Szenajch

from Military Institute of Medicine, Warsaw, Poland
Linked to 5 other reagents on Ximbio.

Dr Luiza Handschuh
Dr Luiza Handschuh

from Institute of Bioorganic Chemistry Polish Academy of Sciences
Linked to 5 other reagents on Ximbio.

Dr Aleksandra Świercz
Dr Aleksandra Świercz

from Institute of Bioorganic Chemistry Polish Academy of Sciences
Linked to 5 other reagents on Ximbio.

Dr Michal Góralski
Dr Michal Góralski

from Institute of Bioorganic Chemistry Polish Academy of Sciences
Linked to 5 other reagents on Ximbio.

Dr Alicja Szabelska-Beręsewicz
Dr Alicja Szabelska-Beręsewicz

from Poznań University of Life Science
Linked to 5 other reagents on Ximbio.

Prof Idzi Siatkowski
Prof Idzi Siatkowski

from Poznań University of Life Science
Linked to 5 other reagents on Ximbio.

Dr Joanna Zyprych-Walczak
Dr Joanna Zyprych-Walczak

from Poznań University of Life Science
Linked to 5 other reagents on Ximbio.

Add an inventor

Invented at

Military Institute of Medicine, Warsaw, Poland
Military Institute of Medicine, Warsaw, Poland

6 reagents listed on Ximbio